Vandetanib

Search with Google Search with Bing

Information
Drug Name
Vandetanib
Description
Entry(CIViC)
6
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
lung adenocarcinoma AKT2 AMPLIFICATION
( ENST00000392038.7 ) AKT2 AMPLIFICATION
( ENST00000392038.7 ) 		C Predictive Supports Sensitivity/Response N/A 1 25982012 Detail
lung adenocarcinoma RET KIF5B-RET C Predictive Supports Sensitivity/Response N/A 2 25982012 Detail
lung non-small cell carcinoma RET UNKNOWN RET FUSION B Predictive Supports Sensitivity/Response Somatic 3 27803005 Detail
lung non-small cell carcinoma RET UNKNOWN RET FUSION B Predictive Supports Sensitivity/Response Somatic 3 27825616 Detail
lung adenocarcinoma RET KIF5B-RET C Predictive Supports Sensitivity/Response Somatic 2 23584301 Detail
breast cancer RET EXPRESSION RET EXPRESSION D Predictive Supports Sensitivity/Response Somatic 2 26686064 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
Case report of a 74-year old woman with EGFR- and ... AKT2 AKT2 AMPLIFICATION
( ENST00000392038.7 ) AKT2 AMPLIFICATION
( ENST00000392038.7 ) 		Sensitivity true CIViC Evidence detail
Case report of a 74-year old woman with EGFR- and ... RET RET KIF5B-RET Sensitivity true CIViC Evidence detail
RET rearrangements involving RET are found in abou... RET RET UNKNOWN RET FUSION Sensitivity true CIViC Evidence detail
We aimed to assess the efficacy and safety of vand... RET RET UNKNOWN RET FUSION Sensitivity true CIViC Evidence detail
A case study of a patient with EGFR, KRAS, BRAF, H... RET RET KIF5B-RET Sensitivity true CIViC Evidence detail
Vandetanib was tested in 4 murine models of patien... RET RET EXPRESSION RET EXPRESSION Sensitivity true CIViC Evidence detail
ZD6474 inhibits vascular endothelial growth factor... KDR KDR EXPRESSION Sensitivity true MMMP detail
NCT ID Status Phase Summary Start date Completion date
NCT01582191 Active, not recruiting Phase 1 Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer May 14, 2012 May 31, 2026
NCT02299999 Active, not recruiting Phase 2 SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer April 7, 2014 December 2024
NCT04211337 Active, not recruiting Phase 3 A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer February 11, 2020 February 28, 2026
NCT01298323 Active, not recruiting Phase 3 Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment February 25, 2011 June 28, 2024
NCT01544140 Completed Phase 1 Study in Healthy Volunteers to Assess the Pharmacokinetics of Midazolam Administered Alone and in Combination With Vandetanib April 2012 July 2012
NCT01561781 Completed Phase 1 Study in Healthy Volunteers to Assess the Pharmacokinetics (PK) of Digoxin Administered Alone and in Combination With Vandetanib March 2012 July 2012
NCT01823068 Completed Phase 2 Vandetanib in Advanced NSCLC With RET Rearrangement November 3, 2014 March 16, 2018
NCT00503711 Completed Phase 1 Phase I Chinese PK September 2006 November 2007
NCT02117167 Completed Phase 2 SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients April 23, 2014 December 2023
NCT02015065 Completed Phase 2 Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors December 14, 2013 December 10, 2019
NCT00508001 Completed Phase 2 Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC) July 2007 June 2009
NCT00514046 Completed Phase 1/Phase 2 Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer July 20, 2007 November 1, 2020
NCT00532909 Completed Phase 1 Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer July 2006 May 2010
NCT00537095 Completed Phase 2 Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer September 28, 2007 November 24, 2021
NCT00418886 Completed Phase 3 Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients January 2007 February 14, 2023
NCT00660725 Completed Phase 1 Study of GemOx and Vandetanib in Advanced Solid Malignancy February 2009 December 2010
NCT00681798 Completed Phase 1 Dose Escalation Study With Zactima and Chemotherapy in Metastatic Pancreas Carcinoma July 2006 June 2009
NCT00312377 Completed Phase 3 ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer May 2006 March 2014
NCT00454116 Completed Phase 2 A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients March 2007 November 2009
NCT00472017 Completed Phase 1 Vandetanib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Diffuse Brainstem Glioma April 2007 October 2011
NCT00364351 Completed Phase 3 Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy August 2006 November 2016
NCT00734890 Completed Phase 1 Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma March 2008 February 2011
NCT00757692 Completed Phase 2 Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer. January 2009 November 2012
NCT00777179 Completed Phase 2 Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy October 2008 December 2011
NCT00821080 Completed Phase 1 Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma October 2008 February 2015
NCT00822887 Completed Phase 1 Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gliomas March 2007 January 2011
NCT00066313 Completed Phase 2 ZD6474 in Treating Patients With Small Cell Lung Cancer May 2003 December 2006
NCT00872989 Completed Phase 2 S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer March 2010 May 2014
NCT00880334 Completed Phase 2 Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC September 2006 May 2015
NCT00496665 Completed Phase 1 ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer July 2007 March 2009
NCT01183559 Completed Phase 1 A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery August 7, 2008 August 2011
NCT01191892 Completed Phase 2 Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer June 2010 September 5, 2016
NCT00500292 Completed Phase 2 A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer March 2007 November 2016
NCT01414426 Completed Phase 2 Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions January 2012 June 1, 2019
NCT01539655 Completed Phase 1 Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib February 2012 September 2012
NCT00862836 Terminated Phase 1/Phase 2 Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD) April 2009 September 2010
NCT00445549 Terminated Phase 2 Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer January 2007 October 2009
NCT00481845 Terminated Phase 2 Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer January 2008 December 2009
NCT00597116 Terminated Phase 2 An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma December 2007 January 2010
NCT00683787 Terminated Phase 2 Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer May 2008 March 2011
NCT00686036 Terminated Phase 2 Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy May 2008 October 2010
NCT00720083 Terminated Phase 2 Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer November 2008 August 2011
NCT00732745 Terminated Phase 1 Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction October 2008
NCT00923247 Terminated Phase 1/Phase 2 A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) February 19, 2009 December 9, 2016
NCT01372813 Terminated Phase 2 Vandetanib to Treat Advanced Kidney Cancer December 2007 June 2010
NCT01934335 Terminated Phase 2 Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer October 2013 December 21, 2018
NCT02495103 Terminated Phase 1/Phase 2 Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma August 26, 2015 February 6, 2020
NCT03630120 Terminated Phase 2 Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer August 6, 2018 December 5, 2019
NCT02239952 Unknown status N/A HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors) November 2014 November 2021
NCT02530411 Unknown status Phase 2 Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer April 2015 December 2020
NCT02638428 Unknown status Phase 2 Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy December 2015 December 2023
NCT02013089 Unknown status N/A A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study December 2013 December 2017
NCT01941849 Withdrawn Phase 1 Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma October 2014 December 2015
NCT00937417 Withdrawn Phase 1 S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors September 2008 September 2009
NCT00601614 Withdrawn Phase 1 Vandetanib and Temozolomide in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery January 2008
NCT04760288 Withdrawn Phase 3 A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). November 30, 2023 April 12, 2035